SUMMARY Thirty four out of 750 patients entered into the Medical Research Council's (MRC) 9th Acute Myeloid Leukaemia Trial had more than 1% basophils (range 1-27%) often with bizarre granulation and primitive forms, a rare finding in this disease. Both normal and abnormal karyotypes were present including abnormalities of 6p, 12p, and the Philadelphia chromosome. Basophilia was found in both "monolineage" and "multilineage" leukaemias and the commonest French-AmericanBritish (FAB) classification group was M2, followed by M4. Basophilia did not seem to be associated with a worse prognosis, although cases with abnormalities of 6p died of disease that was resistant to first line conventional chemotherapy. 
Basophils are rare in normal bone marrow, comprising less than 0-2% of all nucleated cells.' Their role in immediate hypersensitivity reactions is well known but they are not common in other diseases. Increased numbers may be found in myeloproliferative disorders, in particular, chronic myeloid leukaemia (CML), where an increase in numbers may herald the onset of blast transformation.2 In 1984 Pearson drew attention to the presence of increased numbers of marrow basophils (> 1%) in association with a t(6;9) (p23;q34) translocation in acute myeloid leukaemia (AML)3 and in 1985 Daniel et al reported evidence of blast cell maturation towards basophils in cases of AML with a deletion of the short arm of chromosome 12.' Basophils have also been noted in Philadelphia positive "de novo" AML. 5 In 750 cases entered into the MRC's 9th AML trial only 34 cases showed 1% or more basophils of any stage of maturity in the bone marrow.
Material and methods
Patients were entered into the trial from several participating centres in the United Kingdom and Ireland, at the discretion of the local physician or haematologist.
Patients were randomly allocated to 1 + 5 or 3 + 10 DAT as induction chemotherapy. DAT chemotherapy consisted of daunorubicin 50 mg/m2 by intravenous bolus on day 1 or days 1, 3, and 5; cytosine arabinoside 100 mg/m2 by intravenous bolus 12 hourly for five or 10 days; and 6-thioguanine 100 mg/m2 orally 12 hourly for five or 10 days. Patients entering remission were given 2 + 7 DAT then randomised to either MAZE (m-amsa 100 mg/m2 intravenously, 5-azacytidine 100 mg/m2, and etoposide 100 mg/m2
Accepted for publication 2 March 1989 intravenously, each daily for five days), or COAP (cyclophosphamide 600 mg/m2 intravenously, vincristine 1-5 mg/m2 (maximum 2 mg) intravenously, cytosine arabinoside 100 mg/m2 intravenously for five days and prednisolone 60 mg/m2 orally for five days). After completing consolidation, patients were randomised for the last time to stop treatment, or continue with eight further monthly courses of cytosine and 6-thioguanine followed by four courses of COAP.
Bone marrow smears were routinely stained with Romanowsky, Sudan black B, periodic acid Schiff reagent (PAS), dual esterase and iron according to standard cytological methods.6 If sufficient slides were available smears were also stained with toluidine blue.7 Differential counts of 500 cells were performed on Romanowsky stained preparations and further 500 cell counts on toluidine blue stained smears if available.
Cytogenetic studies were performed in Cambridge or at the referring centre using standard culture methods and G-banding. Two patients with Philadelphia chromosomes presented as "de novo" AML but were withdrawn from the trial when the karyotype became known.
Results
Thirty four out of 750 patients entered into the trial showed more than 1% basophils in bone marrow smears and 20 patients (59%) achieved remission (64% for all patients (750) in the same trial). Median survival was about 282 days and median duration of remission has not been reached but is in the region of 18-24 months. Ten patients are still alive at the time of writing. Four patients (case 4, 29, 31, 34) died in remission during consolidation or maintenance 785 Table Karyotype and morphological details ofpatients with 
Discussion
Increased numbers of basophils (with normal morphological detail) have been associated with a t(6;9) Hoyle, Sherrington, Fischer, Hayhoe translocation in AML3 but have not been seen in all cases with t(6;9)."'0 Initially it was thought that basophilia may have been due to the involvement of 9q34 and the abl oncogene as basophilia is common in CML. Two patients in this series (cases 1 and 9), however, had karyotypic abnormalities of 6p23/6p21, suggesting that the 6p breakpoint may be more strongly associated with basophilia than 9q34 in AML. Case 1 of this series has been reported in detail elsewhere."
Fleishman initially drew attention to the presence of a common breakpoint at 6p23 in myeloid leukaemias in a series of five cases which included two with t(6;9) and a case of myelomonocytic leukaemia with t(X;6)(pll;p23).'2 No comment on the presence or absence of basophils is made in this paper, although the two cases with t(6;9) were later included in the series of nine cases by Pearson associating t(6;9) with basophilia. 3 Pearson also gave the karyotypes of five other patients with increased marrow basophils (range 1 75-6&0%). They were as follows: case 83, 46XY, -2, -5, -16, + 3 mar; case 39 46XY/45XY -7; Patient 166 46XY; case 170 45XY-7, del(12) (p1 lpl3)/44XY -7, -13, del(l2); and case 168 46Xdel(Y)(ql2),invl6(pl3q22). There seem to be some chromosomal abnormalities in common between these cases and our series and the deletion of 12p has already been associated with basopilia. 4 Rothenberg reported two cases of AML developing from Philadelphia negative myeloproliferative disorders with prominent basophilia.'3 One of these cases had a normal karyotype and the other trisomy 8. It is very unlikely, despite three patients in our series also having trisomy 8, that this abnormality is associated with basophilia as trisomy 8 is the commonest chromosomal abnormality in haematological malignancies whereas basophilia is relatively rare.
A case of megakaryoblastic leukaemia in a child with Down's syndrome-48XY + 11 + 21,t(l; 15) (breakpoints not specified)-has been described,'4 which on culture differentiated into basophils. The diagnosis of megakaryoblastic leukaemia was based on the distribution of platelet peroxidase (PPO) in the perinuclear space and endoplasmic reticulum on ultrastructural studies, the blasts being undifferentiated and cytochemically negative on light microscopical examination. A similar pattern of PPO with basophil/mast cell granules in the same cell was found in a few cases ofblast cell crisis ofCML in a series of41 patients studied by Parkin et al. ' 5 Some cases of lymphoid blast crisis (CALLA positive) had basophil/ mast cell granules ultrastructurally and some "lymphoid" blasts contained large azurophilic granules which also stained with toluidine blue and PAS. '5 In another study basophil/mast cell granules were seen ultrastructurally in five cases of ALL with a t(4;11) Basophils in acute myeloid leukaemia abnormality. '6 This suggests that primitive basophil leukaemias may well be underdiagnosed.
Wick also commented on the fact that basophil differentiation may be missed and patients erroneously classified as having ALL.'7 Wick described four cases, similar to case 34 in this series, which had a small percentage of blasts with azurophilic granules but the blasts were negative for MPO, Sudan black, PAS, esterase and positive for toluidine blue and acid phosphatase. Three of the four cases had a normal karyotype. Recognition of basophil differentiation by metachromatic staining with toludine blue is important so that the correct chemotherapy can be given.
Bone marrow basophilia was found in six out of 375 cases reviewed by May and Waddell,'8 three of whom had non-malignant conditions and had 1b5%, 2%, and 9% marrow basophils. The authors speculated that bone marrow basophilia in dysplasia and leukaemia may reflect a local response of normal marrow lymphocytes to long term exposure to abnormal secretory or cell surface antigens of the leukaemic cell population, leading to increased T cell derived factors. The in vitro differentiation of basophils from marrow precursors has been shown to be enhanced by the presence of T cell derived factors.'9 One factor, termed basophil-like cell promoting activity,20 stimulates long term growth and also induces differentiation of cells which morphologically and functionally resemble basophils. A second factor, which in contrast to the previous factor stimulates murine IL-3 dependent cells,'l induces the growth of human metachromatically staining cells of an immature morphology with a certain resemblance to mast cells. Basophil-like cell promoting activity does not share biochemical similarities with other well defined human growth factors, while the IL-3 activity has strong resemblance to pluripotential haemopoietic CSF (m-CSF/IL3).20
None of the 34 in this series had increased marrow lymphocytes suggestive of a role for T cell driven proliferation of basophils, but immunophenotyping was not performed. Neither was there a notable increase in clinically important infections at diagnosis which might stimulate the immune system. In case 28 the basophilia may have been related to his concomitant asthma and eczema.
The basophilia in some of these patients, particularly those with a relatively low percentage, may be a result of stimulation by non-lineage specific growth factors or gene products. Multi-CSF or IL3 has been located to 5q23-q3 1,21 which does not seem to have a specific role in this series. Those cases with the most noticeably increased numbers of basophils may be stimulated by more specific growth factors. Serum factors have been shown to have no effect on basophilopoiesis in the culture of marrow from patients 791 with CML, however,22 and it was suggested that increased basophil production was the result of a primary change in the transformed cell.
At present the chromosomal location of any basophil growth factor is not known, but the cytogenic data suggest that the short arms of chromosomes 6 and 12 may be candidate regions. Genes already associated with 6p21 include tumour necrosis factors a and #,23 which help mediate the acute phase response and may also be cytotoxic to certain tumour cells, and the genes for the major histocompatibility complex (MHC); but their relevance to basophilia is not obvious. An oncogene c-kirsten ras 2 has been assigned24 to 12pll-1-pl2-1 and may be relevant to the pathogenesis.
Recently the MIC Cooperative Group25 proposed a complex classification of AML incorporating morphology, immunophenotype, and cytogenics. Specific subgroups designated M2 baso/12p-and Ml t(9;22) have been proposed. The Philadelphia positive cases in our series did not fit this nomenclature, being M7 and M2, respectively, although the cases with a deletion of 12p(pIll;pl3) were classifiable as M2. Four other cases entered into the AML trial had abnormalities of 12p but showed no proliferation or abnormalities of basophils. The brief karyotypes of the patients were as follows: man aged 33, 46XY/45XY, dic(12;21)(pl 1-2,p13); man aged 71, t(l2;17)(pl2,ql 1) +complex; woman aged 64, t(?;12)(?p?) +complex; and man aged 64 t(3;12)(p21;?pl2?p13) + complex. The last case had pronounced eosinophilia (52%) and is similar to other patients with eosinphilia and abnormalities of 12pI3 described by Reene et al. 26 Abnormalities of 12pl2 have also been found in 23 cases of ALL,2' although many of them were CALLA positive, ultrastructural studies looking for basophil granules were not done, and it is not possible to say whether any of these cases were basophil leukaemias that were misdiagnosed, a possibility commented on by Wick." In the original series by Daniel4 only five of 16 patients with abnormalities of 12p had basophil disorders, four of whom had deletions and one a translocation at 12pl3. Although specific deletions of No 12 at p1 lp13 may be associated with basophilia, breakpoints of 12pl13 (or p11/12) do not seem to be associated with basophilia.
Basophilis do not seem to be associated with a worse remission rate but those cases with chromosome abnormalities of6p and 12p do seem to fare badly. The two cases with abnormalities of 6p had disease that was resistant to conventional first line treatment.
Cases of AML with abnormalities of 6p38 10 12 28-33 have done poorly with only eight out of 22 achieving remission, which was shortlived. The longest survivor relapsed after allogeneic bone marrow transplantation and died 18 
